{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:33:50Z","timestamp":1789472030079,"version":"build-2803163510"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We investigated the time course of clinical response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study (TEOSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>TEOSS randomized 119 predominantly outpatient youth ages 8\u201319 years with schizophrenia or schizoaffective disorder to 8 weeks of treatment with molindone, risperidone, or olanzapine. We used proportional hazards regression to determine whether these three antipsychotics differed in the time until clinical response, defined as the time from treatment initiation to the point of achieving a Clinical Global Impressions-Improvement (CGI-I) scale score of 1 (\u201cvery much improved\u201d) or 2 (\u201cmuch improved\u201d) that was maintained until week 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 116 youth who initiated treatment, 56 (48%) achieved clinical response. Among clinical responders, the median (\u00b1interquartile range) time until clinical response was 4.0 (\u00b14.0) weeks for olanzapine, 4.5 (\u00b14.0) weeks for risperidone, and 6.0 (\u00b14.0) weeks for molindone. There were no significant differences in time course for clinical response between medications (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.84). Youth without symptom improvement (CGI-I \u2265 4) after 3 weeks were more likely to be clinical nonresponders at week 8 (relative risk ratio\u2009=\u20091.98, 95% confidence interval 1.29\u20133.05), compared with youth with at-least-minimal symptom improvement after 3 weeks when looking at all antipsychotics combined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      To our knowledge, our study is the first to investigate medication differences in treatment response timing in early onset schizophrenia spectrum disorders. Clinical response times for molindone, risperidone, and olanzapine were not significantly different. Furthermore, while lack of early improvement predicted clinical nonresponse, whether or not to continue antipsychotic treatment after 3 or more weeks without symptom improvement should be based on clinical judgment after weighing potential risks, benefits, and alternatives.\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      Identifier: NCT00053703\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2020.0030","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T09:27:20Z","timestamp":1594114040000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study"],"prefix":"10.1177","volume":"31","author":[{"given":"Jerome H.","family":"Taylor","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."},{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Appel","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Eli","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."},{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Alexander-Bloch","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."},{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Maayan","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel E.","family":"Gur","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."},{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Child Study Center, Yale University, New Haven, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05785yel"},{"key":"e_1_3_1_3_1","article-title":"The 2019 Schizophrenia International Research Society Conference, 10\u201314 April, Orlando, Florida: A summary of topics and trends","volume":"284","author":"Alameda L","year":"2019","unstructured":"Alameda L, , Ashok A, , Avery S, , Bani-Fatemi A, , Berkhout S, , Best M, , Bonfils K, , Colizzi M, , Dauvermann M, , Plessis SD, , Dwyer D, , Eisner E, , Ganesh S, , Hernaus D, , Ithal D, , Kowalchuk C, , Kristensen T, , Lavigne K, , Lee E, , Lemmers-Jansen I, , O'Donoghue B, , Oliver L, , Oluwoye O, , Park MT, , Di Carlo P, , Joaquim HPG, , Pinheiro A, , Ramsay I, , Rodriguez V, , Sami M, , Soni S, , Sonnenschein S, , Taylor J, , Thomas M, , Waterreus A, , Wojtalik J, , Yang Z, , Emsley R, , Kilian S: The 2019 Schizophrenia International Research Society Conference, 10\u201314 April, Orlando, Florida: A summary of topics and trends. Psychiatry Res, 284:112672, 2019.","journal-title":"Psychiatry Res"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.06.009"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.048"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10278"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.11.2063"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2019.08.017"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.743"},{"key":"e_1_3_1_10_1","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study","volume":"49","author":"Findling RL","year":"2010","unstructured":"Findling RL, , Johnson JL, , McClellan J, , Frazier JA, , Vitiello B, , Hamer RM, , Lieberman JA, , Ritz L, , McNamara NK, , Lingler J, , Hlastala S, , Pierson L, , Puglia M, , Maloney AE, , Kaufman EM, , Noyes N, , Sikich L: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. J Am Acad Child Adolesc Psychiatry, 49:583\u2013594, 2010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2012.02.001"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31807083fd"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.05.038"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06349"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0103"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013881"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.164"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp130"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0301"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01308.x"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.008"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.09.006"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3180691779"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"e_1_3_1_27_1","unstructured":"National Institute for Health and Care Excellence: Psychosis and Schizophrenia in Children and Young People: Recognition and Management. London England: Rcpysch Publiciations 2013."},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.12.013"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0044"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv125"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.12.2096"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101329"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.06.004"},{"key":"e_1_3_1_34_1","first-page":"SIGN","article-title":"Management of Schizophrenia: A National Clinical Guideline","author":"Scottish Intercollegiate Guidelines Network","year":"2013","unstructured":"Scottish Intercollegiate Guidelines Network: Management of Schizophrenia: A National Clinical Guideline. Edinburgh,, Scotland: SIGN, 2013.","journal-title":"Edinburgh,"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050756"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.12.021"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.02.002"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0147"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00429-2"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2020.0030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:56Z","timestamp":1777388156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2020.0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/cap.2020.0030"],"URL":"https:\/\/doi.org\/10.1089\/cap.2020.0030","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}